Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended March 31, 2017.